Alexandria Hammond
Stock Analyst at Wolfe Research
(0.78)
# 3,824
Out of 4,429 analysts
47
Total ratings
43.3%
Success rate
-5.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintained: Buy | $1,325 → $1,350 | $1,102.08 | +22.50% | 6 | May 21, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $1,150 → $860 | $612.50 | +40.41% | 2 | May 18, 2026 | |
| PFE Pfizer | Reiterated: Sell | $25 → $26 | $25.08 | +3.67% | 5 | May 13, 2026 | |
| MRK Merck & Co. | Upgraded: Buy | $135 | $115.48 | +16.90% | 3 | Jan 8, 2026 | |
| ABBV AbbVie | Downgraded: Hold | n/a | $230.01 | - | 2 | Jan 8, 2026 | |
| MRNA Moderna | Reiterated: Sell | $20 → $17 | $59.35 | -71.35% | 6 | Nov 20, 2025 | |
| JNJ Johnson & Johnson | Maintained: Buy | $200 → $225 | $231.29 | -2.72% | 7 | Oct 15, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $95 | $55.90 | +69.95% | 3 | Jul 15, 2025 | |
| GILD Gilead Sciences | Initiated Coverage: Buy | $110 → $109 | $124.87 | n/a | 3 | Dec 10, 2024 | |
| AMGN Amgen | Initiated Coverage: Hold | n/a | $344.72 | n/a | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $199.71 | n/a | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $54.70 | n/a | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $150 | $512.88 | n/a | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $550 | $466.79 | n/a | 2 | Aug 2, 2024 |
Eli Lilly and Company
May 21, 2026
Maintained: Buy
Price Target: $1,325 → $1,350
Current: $1,102.08
Upside: +22.50%
Regeneron Pharmaceuticals
May 18, 2026
Reiterated: Buy
Price Target: $1,150 → $860
Current: $612.50
Upside: +40.41%
Pfizer
May 13, 2026
Reiterated: Sell
Price Target: $25 → $26
Current: $25.08
Upside: +3.67%
Merck & Co.
Jan 8, 2026
Upgraded: Buy
Price Target: $135
Current: $115.48
Upside: +16.90%
AbbVie
Jan 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $230.01
Upside: -
Moderna
Nov 20, 2025
Reiterated: Sell
Price Target: $20 → $17
Current: $59.35
Upside: -71.35%
Johnson & Johnson
Oct 15, 2025
Maintained: Buy
Price Target: $200 → $225
Current: $231.29
Upside: -2.72%
BioMarin Pharmaceutical
Jul 15, 2025
Reiterated: Buy
Price Target: $95
Current: $55.90
Upside: +69.95%
Gilead Sciences
Dec 10, 2024
Initiated Coverage: Buy
Price Target: $110 → $109
Current: $124.87
Upside: n/a
Amgen
Nov 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $344.72
Upside: n/a
Nov 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $199.71
Upside: n/a
Nov 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $54.70
Upside: n/a
Aug 7, 2024
Reiterated: Sell
Price Target: $150
Current: $512.88
Upside: n/a
Aug 2, 2024
Reiterated: Buy
Price Target: $550
Current: $466.79
Upside: n/a